MedTrace Logo

Regulation of the Immune System in Response to the Treatment With Tocilizumab in Rheumatoid Arthritis Patients

NCT01633346 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2016-11-11

No results posted yet for this study

Summary

The purpose of this study is to know the level of expression and activation state of different transcription factors of the STAT family (STAT1, STAT3, STAT5A, STAT5B, STAT6) in the hematopoietic cells from tocilizumab treated patients.

Conditions

Sponsors & Collaborators

  • Roche Pharma AG

    collaborator INDUSTRY

  • Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau

    lead OTHER

Principal Investigators

  • Silvia Vidal, PhD · Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-06-30
Primary Completion
2016-07-31
Completion
2016-11-30

Countries

  • Spain

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01633346 on ClinicalTrials.gov